Cargando…

Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures

INTRODUCTION: Lusutrombopag is an oral thrombopoietin receptor agonist (TPO-RA). Clinical trials have shown lusutrombopag’s efficacy in reducing need for preoperative platelet transfusion in patients with chronic liver disease (CLD) and severe thrombocytopenia. This analysis assessed efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orme, Michelle E., Bentley, Roy, Marcella, Stephen, Peck-Radosavljevic, Markus, Perard, Rodolphe, Wedemeyer, Heiner, Yoshiji, Hitoshi, Agarwal, Kosh, Dusheiko, Geoffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402754/ https://www.ncbi.nlm.nih.gov/pubmed/35836089 http://dx.doi.org/10.1007/s12325-022-02235-w

Ejemplares similares

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)
por: Peck‐Radosavljevic, Markus, et al.
Publicado: (2019)

A cost‐effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan
por: Miki, Norikane, et al.
Publicado: (2021)

Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag
por: Brown, Robert S., et al.
Publicado: (2021)

Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
por: Ding, Zhenbin, et al.
Publicado: (2022)

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures
por: Nishida, Yuno, et al.
Publicado: (2020)

Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance
por: Sasaki, Ritsue, et al.
Publicado: (2019)

Bleeding events in lusutrombopag‐treated thrombocytopenic patients
por: Giannini, Edoardo Giovanni, et al.
Publicado: (2021)

Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child–Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance
por: Flamm, Steven L., et al.
Publicado: (2022)

A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series
por: Biolato, Marco, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Katsube, Takayuki, et al.
Publicado: (2019)

Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment
por: Sato, Shuichi, et al.
Publicado: (2017)

Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries
por: Mitchell, Tim, et al.
Publicado: (2022)

Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia
por: Ishikawa, Toru, et al.
Publicado: (2019)

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study
por: Nomoto, Hiroaki, et al.
Publicado: (2020)

Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease
por: Yoshida, Manami, et al.
Publicado: (2021)

Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report
por: Kaneko, Takeshi, et al.
Publicado: (2021)

Relationship between response to lusutrombopag and splenic volume
por: Uojima, Haruki, et al.
Publicado: (2018)

Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures
por: Takada, Hitomi, et al.
Publicado: (2019)

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
por: Sakamaki, Akira, et al.
Publicado: (2017)

Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report
por: Sasaguri, Tomoko, et al.
Publicado: (2018)

Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS
por: Wang, Bo, et al.
Publicado: (2020)

Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters
por: Katsube, Takayuki, et al.
Publicado: (2020)

Drug Therapy for Advanced-Stage Liver Cancer
por: Peck-Radosavljevic, Markus
Publicado: (2014)

Editorial
por: Peck-Radosavljevic, Markus
Publicado: (2020)

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure
por: Satapathy, Sanjaya K., et al.
Publicado: (2023)

Prothrombotic immune thrombocytopenia after COVID-19 vaccination
por: Tiede, Andreas, et al.
Publicado: (2021)

Review article: systemic treatment of hepatocellular carcinoma
por: Pinter, Matthias, et al.
Publicado: (2018)

Towards the elimination and eradication of hepatitis B
por: Dusheiko, Geoffrey
Publicado: (2015)

Hepatitis B prevalence in pregnant women in China: Progress and realities
por: Dusheiko, Geoffrey
Publicado: (2021)

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C
por: Childs, Kate, et al.
Publicado: (2019)

Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures
por: Mastrorilli, Giulia, et al.
Publicado: (2022)

A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study
por: Yoshida, Hideo, et al.
Publicado: (2023)

Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection
por: Jaroszewicz, Jerzy, et al.
Publicado: (2012)

Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?—the SCOOP-2 trial experience
por: Peck-Radosavljevic, Markus, et al.
Publicado: (2020)

Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
por: Pinter, Matthias, et al.
Publicado: (2021)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
por: Nilles, Kathy M., et al.
Publicado: (2019)

A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis
por: Acaster, Sarah, et al.
Publicado: (2013)

Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update
por: Lok, James, et al.
Publicado: (2021)

Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study
por: Ding, Jing-Nuo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bgdg20i6rbeoahlc5elhm5d188